M. Roelvink

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Giuseppe Giaccone, Cornelis J. A. Punt, Rita Ruijter et al. · PubMed · 2002 · 507 citations

Medicine, Oncology, Pharmacology +17

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report

Bruno Coudert, Alan Anthoney, Walter Fiedler et al. · European Journal of Cancer · 2001 · 84 citations

Medicine, Oncology, Thoracic Oncology +5

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

Peter C.C. Fong, David S. Boss, C. P. Carden et al. · Journal of Clinical Oncology · 2008 · 83 citations

Medicine, Oncology, Pharmacology +17

First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

Timothy A. Yap, David S. Boss, Peter C.C. Fong et al. · Journal of Clinical Oncology · 2007 · 76 citations

Medicine, Oncology, Pharmacology +15

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation

Ian Judson, T. Cerny, Ron Epelbaum et al. · Annals of Oncology · 1997 · 54 citations · Full text

Medicine, Oncology, Cancer Pharmacology +9